Enrolling by invitationPhase 2NCT07344220
Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate
Studying Familial pancreatic carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoag Memorial Hospital Presbyterian
- Principal Investigator
- Carlos Becerra, MDHoag Memorial Hospital Presbyterian
- Intervention
- DZ-002 - 5 mg/kg, 6 mg/kg, or 7 mg/kg(drug)
- Enrollment
- 39 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2029
Study locations (1)
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Collaborators
Da Zen Theranostics Inc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07344220 on ClinicalTrials.govOther trials for Familial pancreatic carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06744595Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic CancerMayo Clinic
- RECRUITINGNCT04743479Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)Changhai Hospital
- ACTIVE NOT RECRUITINGNCT04247503Cohort Study of Pancreatic Cancer RiskMayo Clinic
- ACTIVE NOT RECRUITINGNCT03060720Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized TherapyDana-Farber Cancer Institute
- RECRUITINGNCT01102569Pancreatic Cancer GeneticsColumbia University
- ACTIVE NOT RECRUITINGNCT00835133Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and MelanomaMayo Clinic